Voyager Therapeutics (NASDAQ:VYGR) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Voyager Therapeutics (NASDAQ:VYGR – Get Rating) in a research report released on Thursday morning. The brokerage issued a buy rating on the stock.

Separately, Oppenheimer began coverage on Voyager Therapeutics in a report on Thursday, March 9th. They set an outperform rating and a $14.00 price objective for the company.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR opened at $7.92 on Thursday. Voyager Therapeutics has a 1-year low of $4.61 and a 1-year high of $10.81. The business has a 50-day moving average price of $8.22 and a two-hundred day moving average price of $6.70.

Insiders Place Their Bets

In other news, major shareholder Rock Ventures Iii L.P. Third sold 50,000 shares of the business’s stock in a transaction dated Wednesday, January 25th. The stock was sold at an average price of $9.22, for a total transaction of $461,000.00. Following the completion of the transaction, the insider now directly owns 5,123,933 shares in the company, valued at approximately $47,242,662.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Ecor1 Capital, Llc sold 110,000 shares of the business’s stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $8.50, for a total transaction of $935,000.00. Following the completion of the transaction, the insider now directly owns 3,851,507 shares in the company, valued at approximately $32,737,809.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Rock Ventures Iii L.P. Third sold 50,000 shares of the business’s stock in a transaction dated Wednesday, January 25th. The stock was sold at an average price of $9.22, for a total value of $461,000.00. Following the transaction, the insider now owns 5,123,933 shares of the company’s stock, valued at $47,242,662.26. The disclosure for this sale can be found here. In the last three months, insiders sold 1,035,636 shares of company stock valued at $8,724,631. 22.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Armistice Capital LLC grew its position in shares of Voyager Therapeutics by 32.4% in the 3rd quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock valued at $20,104,000 after purchasing an additional 832,000 shares during the period. Hillsdale Investment Management Inc. grew its position in shares of Voyager Therapeutics by 347.3% in the 3rd quarter. Hillsdale Investment Management Inc. now owns 87,967 shares of the company’s stock valued at $521,000 after purchasing an additional 68,300 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in shares of Voyager Therapeutics by 11.6% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 37,788 shares of the company’s stock valued at $224,000 after purchasing an additional 3,933 shares during the period. Bailard Inc. acquired a new position in shares of Voyager Therapeutics in the 3rd quarter valued at approximately $171,000. Finally, Gamco Investors INC. ET AL bought a new stake in Voyager Therapeutics in the 4th quarter valued at approximately $73,000. 59.58% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

(Get Rating)

Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.